LUNG CANCER

Acclaim-2 has opened enrollment for patients with late-stage non-small cell lung cancer and will begin screening patients for their eligibility to participate in the trial.

The combination of RBN-2397 and pembrolizumab has been dosed in the first patient with squamous cell carcinoma of the lung who is enrolled in a new phase 1b/2 clinical trial.

Use of trilaciclib prior to chemotherapy demonstrated a substantial burden of myelosuppressive hematologic adverse events within the patients with extensive-stage small-cell lung cancer.

A significant proportion of patients who complete 2 years of immune checkpoint inhibitor treatment experience long-term progression-free survival.

The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.

With larotrectinib treatment, patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Findings show adjuvant pembrolizumab to significantly improve disease-free survival in patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

The FDA has approved the FoundationOne CDx as a companion diagnostic to identify patients with non–small cell lung cancer with tumors that harbor EGFR exon 19 deletions or exon 21 substitutions.

During a Targeted Oncology case-based roundtable event, David P. Carbone, MD, PhD, discussed molecular testing and treatment for a patient with late-stage non–small cell lung cancer.

Adding toripalimab to chemotherapy as frontline treatment for advanced non–small cell lung cancer crossed the boundary for statistical significance in CHOICE-01, meeting 2 study end points.

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

Dosing has begun in patients with advanced non–small cell lung cancer in the phase 1/2 Acclaim-1 clinical trial of quaratusugene ozeplasmid in combination with osimertinib after disease progression on osimertinib alone.

Nivolumab in combination with platinum-doublet chemotherapy has been granted FDA approval as neoadjuvant treatment for adult patients with resectable non-small cell lung cancer.

Solange Peters, MD, PhD, discusses the design of the CheckMate743 study of doublet immunotherapy for patients with malignant pleural mesothelioma.

According to retrospective data, racial disparities among patients being screened for lung cancer have decreased.

Jorge Nieva, MD, explains how international drug developers should approach the approval application process after a biologics license application for sintilimab plus chemotherapy for the treatment of nonsquamous non–small cell lung cancer was not successful.

The FDA will conduct a speedy review of the supplemental biologics license application filed for nivolumab in combination with chemotherapy and granted it priority review for the neoadjuvant treatment of patients with resectable non–small cell lung cancer.

Jorge Nieva, MD, discusses how a future clinical trial of sintilimab injection plus chemotherapy should look in order to achieve FDA approval for the treatment of patients with nonsquamous non–small cell lung cancer.

Jorge Nieva, MD, discusses why he voted differently from the other members of the FDA’s Oncologic Drug Advisory Committee regarding sintilimab in combination with chemotherapy for the first-line treatment of patients with nonsquamous non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.

Jorge Nieva, MD, discusses what’s needed for frontline sintilimab plus chemotherapy to have a future in United States patients with nonsquamous non–small cell lung cancer after a negative ODAC vote.

Positive phase 1 results of TQ-B2450 combined with anlotinib have lead to a phase 3 study of the combination versus pembrolizumab in patient with PD-L1 positive advanced non–small cell lung cancer.

Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.

In an interview with Targeted Oncology, Jorge Nieva, MD, provided a recap of the recent ODAC meeting and explained his stance against further research for frontline sintilimab plus chemotherapy for the treatment of patients with nonsquamous NSCLC.

During a Targeted Oncology case-based roundtable event, Roy S. Herbst, MD, PhD, and Joshua K. Sabari, MD, discussed molecular testing and the use of immune checkpoint inhibitors with participants.

The FDA’s Oncologic Drug Advisory Committee has voted against approval of the biologics license application for sintilimab plus pemetrexed and platinum-based chemotherapy for the treatment of nonsquamous non–small cell lung cancer without further clinical trial research.

Julie Renee Brahmer, MD, MSc, discusses upcoming and recent trials that may change the sequencing of targeted therapies in patients with locally advanced non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.